Beta Bionics, Inc.
BBNXNasdaq
$17.29
↑ +2.3%Jul 17 close · end-of-day
Price
1Y↑ +36.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$768.3M
Enterprise Value
$568.8M
P/E
—
P/S
7.0
P/B
2.8
EV/EBITDA
—
PEG
—
FCF Yield
-8.0%
Dividend Yield
—
Revenue (TTM)
$110.2M
Net Income (TTM)
-$66.4M
Free Cash Flow (TTM)
-$61.1M
Gross Margin
57.1%
Operating Margin
-70.1%
Net Margin
-60.3%
ROE
-24.5%
ROIC
-85.2%
Debt / Equity
—
Net Cash
$199.5M
Return 1Y
+31.3%
Company profile
We are a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Our principal executive offices are located at 11 Hughes, Irvine, California.
- CEO
- Sean Saint
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 294
- Headquarters
- California
- Website
- www.betabionics.com
Management & directors
- Feider StephenChief Financial Officer
- Hopman MarkChief Commercial Officer
- Mensinger MikeChief Product Officer
- Russell Steven JonChief Medical Officer
- Saint SeanPresident & CEO
Roles derived from SEC Form 4 filings.
Earnings
BBNX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$27.6M↑ +56.6%
Diluted EPS-$0.49↓ -47.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $12.0M | $65.1M | $100.3M |
| Gross profit | $6.3M | $35.9M | $55.5M |
| Operating income | -$35.9M | -$45.3M | -$71.7M |
| Net income | -$44.1M | -$54.8M | -$73.2M |
| Diluted EPS | -$8.31 | -$8.60 | -$1.81 |
| Operating cash flow | -$32.4M | -$48.3M | -$50.9M |
| Free cash flow | -$32.8M | -$51.7M | -$56.2M |
| Gross margin | 52.6% | 55.1% | 55.4% |
| Operating margin | -298.9% | -69.5% | -71.5% |
| Net margin | -367.6% | -84.1% | -73.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.0M | $16.7M | $20.4M | $17.6M | $23.2M | $27.3M | $32.1M | $27.6M |
| Gross profit | $8.1M | $8.9M | $11.7M | $9.0M | $12.5M | $15.1M | $18.9M | $16.4M |
| Operating income | -$11.8M | -$11.0M | -$13.0M | -$18.6M | -$19.9M | -$17.0M | -$16.1M | -$24.3M |
| Net income | -$14.5M | -$9.7M | -$18.1M | -$28.7M | -$16.9M | -$14.2M | -$13.5M | -$21.9M |
| Diluted EPS | -$2.37 | -$1.46 | -$2.70 | -$0.93 | -$0.39 | -$0.33 | -$0.16 | -$0.49 |
| Operating cash flow | -$12.2M | -$9.6M | -$14.3M | -$20.0M | -$13.6M | -$8.7M | -$8.6M | -$23.8M |
| Free cash flow | -$12.7M | -$11.5M | -$14.8M | -$20.3M | -$15.4M | -$10.0M | -$10.5M | -$25.2M |
| Gross margin | 53.7% | 53.4% | 57.2% | 50.9% | 53.8% | 55.5% | 59.0% | 59.5% |
| Operating margin | -78.3% | -65.7% | -63.8% | -105.7% | -85.5% | -62.5% | -50.2% | -87.9% |
| Net margin | -96.1% | -58.3% | -88.6% | -162.5% | -72.6% | -52.1% | -41.9% | -79.3% |
Company news
May 26, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-29 | Feider Stephen· Chief Financial Officer | Sale | 4,896 | $17.03 | $83,380.84 | filing |
| 2026-06-29 | Feider Stephen· Chief Financial Officer | Sale | 4,896 | $17.03 | $83,380.84 | filing |
| 2026-06-29 | Feider Stephen· Chief Financial Officer | Option exercise | 4,896 | $5.10 | $24,969.60 | filing |
| 2026-06-29 | Feider Stephen· Chief Financial Officer | Option exercise | 4,896 | $5.10 | $24,969.60 | filing |
| 2026-06-26 | Feider Stephen· Chief Financial Officer | Sale | 5,104 | $17.05 | $87,006.36 | filing |
| 2026-06-26 | Feider Stephen· Chief Financial Officer | Sale | 5,104 | $17.05 | $87,006.36 | filing |
| 2026-06-26 | Feider Stephen· Chief Financial Officer | Option exercise | 5,104 | $5.10 | $26,030.40 | filing |
| 2026-06-26 | Feider Stephen· Chief Financial Officer | Option exercise | 4,982 | $5.10 | $25,408.20 | filing |
| 2026-06-24 | Jones Christy | Sale | 1,406 | $15.00 | $21,090.00 | filing |
| 2026-06-24 | Hopman Mark· Chief Commercial Officer | Sale | 1,258 | $15.01 | $18,880.44 | filing |
| 2026-06-04 | Jones Christy | Sale | 2,811 | $14.00 | $39,354.00 | filing |
| 2026-06-04 | Hopman Mark· Chief Commercial Officer | Sale | 275 | $12.31 | $3,385.25 | filing |
| 2026-06-02 | Saint Sean· President & CEO | Sale | 16,872 | $12.61 | $212,706.99 | filing |
| 2026-06-02 | Feider Stephen· Chief Financial Officer | Sale | 6,676 | $12.61 | $84,165.00 | filing |
| 2026-06-02 | Hopman Mark· Chief Commercial Officer | Sale | 5,329 | $12.61 | $67,183.24 | filing |
| 2026-06-02 | Mensinger Mike· Chief Product Officer | Sale | 4,378 | $12.61 | $55,193.88 | filing |
| 2026-06-02 | Russell Steven Jon· Chief Medical Officer | Sale | 4,222 | $12.61 | $53,227.18 | filing |
| 2026-05-22 | Lezack Adam | Sale | 998 | $11.21 | $11,187.58 | filing |
| 2026-05-21 | Jones Christy | Sale | 1,998 | $9.95 | $19,880.10 | filing |
| 2026-05-21 | Lezack Adam | Sale | 1,000 | $9.95 | $9,950.00 | filing |
| 2026-05-21 | CARNEY SEAN | Award | 16,965 | $0.00 | $0.00 | filing |
| 2026-05-21 | Lezack Adam | Award | 16,965 | $0.00 | $0.00 | filing |
| 2026-05-21 | MICHEL GERARD J | Award | 16,965 | $0.00 | $0.00 | filing |
| 2026-05-21 | Jones Christy | Award | 16,965 | $0.00 | $0.00 | filing |
| 2026-05-21 | Palasis Maria | Award | 16,965 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.